Core Viewpoint - Chromatography technology is a crucial analytical method driving scientific breakthroughs and industrial upgrades, with advancements in multidimensional, combined, and intelligent applications across various fields such as life sciences, environmental monitoring, food safety, and precision medicine [1][2]. Event Overview - The 10th Chromatography Network Conference (iCC 2025) will be held on September 4-5, 2025, organized by Instrument Information Network in collaboration with the North American Chinese Chromatography Association (CACA) [1][3]. Conference Focus Areas - The conference will feature four main sessions: 1. Cutting-edge technology session focusing on innovative chromatographic methods [1]. 2. Food and environmental applications session addressing new standards and applications in PFAS detection, carbohydrate analysis, and food flavor analysis [1]. 3. Pharmaceutical research session with insights from renowned pharmaceutical scientists on drug development and quality control challenges [1]. 4. Domestic chromatography technology session showcasing breakthroughs from local enterprises [1]. Conference Schedule Highlights - September 4: - Presentations on low-abundance compound analysis, innovative gas chromatography applications, and therapeutic protein drug analysis [4]. - Afternoon sessions on PFAS analysis and new standards for environmental air particulate matter [4]. - September 5: - Focus on pharmaceutical research with discussions on nitrosamine risks in drugs and quality control methods for protein drugs [5]. - A showcase of domestic chromatography technology and applications, highlighting the achievements of local companies [5]. Notable Speakers - The conference will feature experts from various institutions, including: - Professor Feng Yuqi from Wuhan Textile University, specializing in chromatographic applications [7]. - Professor Huang Jun from Tsinghua University, focusing on PFAS analysis methods [8]. - Senior Scientist Nan He from AbbVie, discussing nitrosamine risks in pharmaceuticals [8].

其中，集中竞价减持公司股份不超过4,038,100股，大宗交易减持公司股份不超过6,767,726股。本次 减持计划为深圳纳微股东之一陈荣华根据个人资金需求减持间接持有的公司股份，公司实际控制人、董 事长江必旺博士不减持公司股份。 | 股东名称 | 深圳市纳微科技有限公司 | | --- | --- | | 计划减持数量 | 不超过:10,805,826 股 | | 计划减持比例 | 不超过:2.6759% | | 减持方式及对应减持数 | 集中竞价减持,不超过:4,038,100 股 | | 量 | 大宗交易减持,不超过:6,767,726 股 | | 减持期间 | 2025年9月22日~2025年12月21日 | | 拟减持股份来源 | IP0 前取得 | | 拟减持原因 | 股东之一陈荣华先生个人资金需求 | 截至公告日，公司股东深圳纳微持有公司股份71,406,992股，占公司总股本的17.6831%，其中无限 售条件的流通股71,406,992股。上述股份为公司首次公开发行前取得的股份，并已于2024年6月24日起上 市流通。深圳纳微股东分别为BIWANG JACK JIANG（中文名：江必旺）博士 ...

Summary of Key Points Core Viewpoint - On August 29, Guizhou Moutai announced plans for a significant share buyback, while 13 other listed companies disclosed their intentions to reduce shareholdings [1][2]. Group 1: Guizhou Moutai - The controlling shareholder of Guizhou Moutai intends to increase its stake by purchasing shares worth between 3 billion to 3.3 billion yuan [2]. Group 2: Companies Reducing Holdings - Several companies announced share reductions, including: - Siyi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce its stake by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their stake by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce his stake by up to 0.0615% [2]. - Aorite: Tian Tai Bolong plans to reduce its holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce his stake by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce his holdings by up to 1% [2].

Summary of Key Points Core Viewpoint - On August 29, 2023, Guizhou Moutai announced plans for significant stock buybacks, while 13 other listed companies disclosed their intentions to reduce shareholdings, indicating a mixed sentiment in the market regarding stock ownership adjustments [1][2]. Group 1: Stock Buybacks - Guizhou Moutai's controlling shareholder intends to increase their stake by purchasing between 3 billion to 3.3 billion yuan worth of company shares [2]. Group 2: Stock Reductions - Several companies announced share reductions, including: - Sayi Information: Five actual controllers plan to reduce their holdings by up to 3% [2]. - Galaxy Magnetics: Director He Jinzhu plans to sell no more than 460,000 shares [2]. - Pinwo Food: The controlling shareholder Wang Mu intends to reduce his stake by up to 3% [2]. - Dike Co., Ltd.: Shareholders from Wuxi Diyin Technology, Wuxi Saide Technology, and Wuxi Shanghui Jia plan to reduce their holdings by up to 1% [2]. - Hengguang Co., Ltd.: Shareholder Xiangjiang Investment plans to reduce holdings by up to 2.99% [2]. - New Open Source: Deputy General Manager Zou Xiaowen plans to sell no more than 125,200 shares [2]. - Nawei Technology: Shareholders intend to reduce their holdings by up to 2.6759% [2]. - Aojing Medical: Shareholders plan to reduce their holdings by up to 1% [2]. - Huasheng Tiancai: Director Wang Weihang and Supervisor Qian Jiying plan to reduce their holdings by up to 0.9984% [2]. - Kosen Technology: Director Tan Chai Hau plans to reduce holdings by up to 0.0615% [2]. - Aoyue Technology: Tian Tai Bolong plans to reduce holdings by up to 0.54% [2]. - Zhejiang Wen Film: Shareholder Qian Wenlong plans to reduce holdings by up to 0.4308% [2]. - Chenxin Pharmaceutical: Shareholder Shi Sihua plans to reduce holdings by up to 1% [2].

Core Viewpoint - Nanwei Technology (688690.SH) announced that Mr. Chen Ronghua intends to reduce his shareholding in the company through a plan to sell all shares indirectly held by Shenzhen Nanwei [1] Group 1 - Mr. Chen Ronghua has sent a notice regarding his share reduction plan [1] - The reduction involves all shares held indirectly by Shenzhen Nanwei [1]

证券代码：688690 证券简称：纳微科技 公告编号：2025-031 苏州纳微科技股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 注：以上持股比例差异是由四舍五入造成的，并非数据错误。 2 股东名称 深圳市纳微科技有限公司 股东身份 控股股东、实控人及一致行动人 √是 □否 直接持股 5%以上股东 √是 □否 董事、监事和高级管理人员 □是 √否 其他： 持股数量 71,406,992股 持股比例 17.6831% 当前持股股份来源 IPO 前取得：71,406,992股 上述减持主体存在一致行动人： 大股东及其一致行动人过去 12 个月内减持股份情况 股东名称 减持数量 （股） 减持比例 减持期间 减持价格区间 （元/股） 前期减持计划 披露日期 深圳市纳微 科技有限公 司 6,690,000 1.6567% 2024/9/26 ～ 2024/12/24 16.3-19.10 2024/8/31 苏州纳研管 理咨询合伙 3,355,5 ...

Group 1 - The core point of the article is that Chen Ronghua plans to reduce his shareholding in Nawi Technology (688690.SH) through a share reduction plan [1] - Chen Ronghua intends to sell a total of up to 10,805,826 shares, which represents 2.6759% of the company's total share capital [1] - The share reduction will occur within three months starting from 15 trading days after the announcement, utilizing both centralized bidding and block trading methods [1] Group 2 - The plan includes a maximum of 4,038,100 shares to be sold through centralized bidding and up to 6,767,726 shares through block trading [1] - The share reduction is based on Chen Ronghua's personal financial needs, while the company's actual controller and chairman, Dr. Jiang Biwang, will not reduce his shareholding [1]

Core Viewpoint - Nanwei Technology (688690.SH) announced that shareholder Chen Ronghua plans to reduce his indirect holdings by up to 10.8058 million shares, accounting for 2.6759% of the company's total share capital, from September 22, 2025, to December 21, 2025. The company's actual controller and chairman, Dr. Jiang Biwang, will not reduce his shareholdings [1] Summary by Category - Shareholder Actions - Chen Ronghua intends to reduce his indirect shareholdings through centralized bidding and block trading [1] - The total number of shares to be reduced is up to 10.8058 million [1] - Company Ownership Structure - The planned reduction represents 2.6759% of the company's total share capital [1] - Dr. Jiang Biwang, the actual controller and chairman, will not participate in any share reduction [1] - Timeline - The reduction period is set from September 22, 2025, to December 21, 2025 [1]

Financial Performance - Company reported a total revenue of 414 million yuan for the first half of 2025, representing a year-on-year increase of 21.74% [1] - Net profit attributable to shareholders reached 63.31 million yuan, up 40.52% year-on-year [1] - Gross margin stood at 72.06%, a slight decrease of 0.5% compared to the previous year, while net margin increased by 23.4% to 15.86% [1] - Total operating expenses were 132 million yuan, accounting for 32.0% of revenue, down 5.96% year-on-year [1] Key Financial Metrics - Earnings per share (EPS) increased by 41.07% to 0.16 yuan [1] - Operating cash flow per share rose significantly by 80.01% to 0.06 yuan [1] - The company's return on invested capital (ROIC) was 4.31% last year, indicating a relatively weak capital return [3] - The company’s historical median ROIC since listing is 10.6%, with the worst year being 2023 at 3.31% [3] Strategic Initiatives - Company emphasizes a customer-centric marketing strategy, focusing on building strategic partnerships with key clients [5] - Revenue from strategic clients in the biopharmaceutical sector accounted for approximately 50% of sales in 2024, showcasing the effectiveness of deepening strategic collaborations [5] - The company aims to enhance customer satisfaction and leverage strategic client relationships to drive revenue growth [5] Fund Holdings - The largest fund holding in the company is from Huatai-PineBridge, with a total of 1.0052 million shares newly entered into the top ten holdings [4] - Other funds that have newly entered the top ten holdings include Bosera Health Growth and Bosera Health Life, indicating growing institutional interest [4]

证券代码：301300 证券简称：远翔新材 公告编号：2025-029 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □是 √否 公司经本次董事会审议通过的利润分配预案为：以实施权益分派的股权登记日登记的公司总股本扣减公 司回购专用证券账户中股份为基数，向全体股东每10股派发现金红利4元（含税），送红股0股（含 税），不以公积金转增股本。 √适用 □不适用 是否以公积金转增股本 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 单位：股 ■ 注：前10名股东中存在回购专户"福建远翔新材料股份有限公司回购专用证券 ...